Table 3.
Source | Our study | Imuetinyan et al. [18] | Mawanda et al. [19] | Ranque et al. [34] | Ranque et al. [34] | Ranque et al. [34] | Ranque et al. [34] |
Country | Kinshasa, DRC | Nigeria (16) | Kampala, Uganda (17) | Yaoundé, Cameroon (30) | Abidjan, Ivory Coast (30)a | Bamako, Mali (30)a | Dakar, Senegal (30)a |
Nature of the study | Cross-sectional | Cross-sectional and descriptive | Cross-sectional | Cross-sectional | Cross-sectional | Cross-sectional | Cross-sectional |
Study period | August 2011 and March 2012 | November 2006– February 2007 | November 2007 and April 2008 | February 2011– December 2013 | February 2011– December 2013 | February 2011– December 2013 | February 2011– December 2013 |
Number of patients | 150 | 69 | 305 | 503 | 337 | 404 | 668 |
Frequency, male (%) | 49 | 61 | 48 | 50 | 44 | 43 | 46 |
Age (years) | Median 8 (IQR 2–18) | 8.8 (±4.7) | 9.7 (±4.9) | Median 13 (IQR 7–21) | Median 15 (IQR 10–23) | Median 17 (IQR 11–24) | Median 15 (IQR 10–22) |
Prevalence of microalbuminuria (%) | 18.5 | 20.3 | 28.2 | 39 | 16 | 38 | 23 |
Cohort including Sβ0 patients.